| Source: |
Streptomyces griseolus |
| Synonyms |
Flagecidin
IUPAC Name:
[(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl]
|
| Description: |
Anisomycin is a protein synthesis inhibitor. It binds to
the
60S ribosomal
subunits and prevents the formation of peptide
bond, and consequently, the chain elongation. |
| CAS number: |
22862-76-6 |
| Merck index: |
13, 673 |
| Molecular weight: |
265.3 |
| Structure: |
 |
| Molecular Formula: |
C14H19NO4 |
| Canonical SMILES: |
CC(=O)OC1C(CNC1CC2=CC=C(C=C2)OC)O |
Solubility
information: |
Anisomycin is also soluble in DMSO,
Ethyl-Acetate, Dichloromethane. Slightly soluble in
water |
| Specifications | |
| Appearance: |
White powder |
| Purity: |
At least 98% by TLC |
| λmax: |
|
| Melting point |
139°C-143°C |
| Solubility |
Clear colorless solution at 10 mg of
Anisomycin in 1 ml of Ethyl Acetate |
| Storage |
+4°C. Protect from light. |
| Applications |
Originally discovered by Sobin and
Tanner in 1954, Anisomycin was identified as an
antibiotic active against protozoa such as Trichomonas
and fungi and yeasts, and was considered as a potential
human anti-candidal and anti-amoebic drug.
Sobin, B. A., and F. W. Tanner,
Jr. 1954. Anisomycin, a new antiprotozoa antibiotic.
J. Am. Chem. Soc. 76:4053.
As such, Anisomycin was put by GONZALEZ CONSTANDSE
to clinical trials in 1955:
Anisomycin in intestinal
amebiasis; study of 30 clinical cases
Prensa Med Mex. 1956 Sep-Dec;21(7-10):114-5
Anisomycin is also proposed as a potential
psychiatric drug, as it is shown to affect protein
synthesis an Amygdala, a brain part involved in memory(1).
The earliest usage of Anisomycin in research on
memory biochemistry was made by Jonec and
Walsterlain in 1979 . Again, this property of
Anisomycin is ascribed to its ability to inhibit protein
synthesis.
Effect of inhibitors of protein
synthesis on the development of kindled seizures
in rats.
Jonec V, Walsterlain CG.
Exp Neurol. 1979 Dec;66(3):524-32
Recently, publications appear showing the
immunomodulating properties on Anisomycin. This
discovery leads to researches on the potential use of
Anisomycin in transplantation:
Anisomycin inhibits the behaviors of T cells
and the allogeneic skin transplantation in
mice.
Xing F et al,
J Immunother. 2008 Nov-Dec;31(9):858-70
In the field of cell-signaling research,
Anisomycin is used as an activator of kinase cascades in
mammalian cells, especially the stress-activated Protein
Kinase (SAPK2/p38MAPK) and p46/54JNK
Anisomycin is a selective ingredientof Martin Lewis
Agar, a bacteriological solid medium used for isolation
of
pathogenic Neisseria
species.
Martin, J. E.,
Jr., and J. S. Lewis. 1977. Anisomycin: improved
antimycotic activity in modified Thayer-Martin
medium. Public Health Lab. 35:53-62
|
| Warnings |
|
| Related products |
|
| | For Research use only. Not
for Human or Drug use
GMP/API grade available on request
Anisomycin by
Fermentek is not produced from or contains any ingredients from animal
origin.
No genetically modified organisms are used. |
| Publications | |
| |
(1)
Barrientos RM, O'Reilly RC, Rudy JW.
Anisomycin injection impaired context memory ....
Behav Brain
Res. 2002 Aug 21;134(1-2):299-306. |
| |
Freeman FM, Rose SP, Scholey AB.
Two time windows of anisomycin-induced amnesia for
passive avoidance training in the day-old chick.
Neurobiol Learn Mem. 1995 May;63(3):291-5. |
| |
Butera PC, Campbell RB, Bradway DM.
Antagonism of estrogenic effects on feeding behavior by
central implants of anisomycin.
Brain Res. 1993
Oct 8;624(1-2):354-6. |
| |
Staubli U, Faraday R, Lynch G.
Pharmacological dissociation of memory: anisomycin, a
protein synthesis inhibitor, and leupeptin, a protease
inhibitor, block different learning tasks.
Behav
Neural Biol. 1985 May;43(3):287-97. |
|
|
